OnCo

Sign in to keep your watchlist

Your watched pages live in this browser. Sign in with an email link and OnCo keeps the same list on every device you use. Only your email address and your watchlist are stored.

Intraductal papillary mucinous neoplasm and other pancreatic cystic precursors: lines of therapy

Cancer page →

5 standard-of-care settings across 3 lines and 2 biomarker subgroups. Rows come from the cancer page's standard of care; the grid places each on its line and subgroup.

LineAll comersRisk group
Screening, prevention and diagnosis1·
Early / localised·1
Other settings3·

Screening, prevention and diagnosis

SubgroupSettingApproachProducts and trialsEvidence
All comersSurveillanceMRI or endoscopic ultrasound at intervals set by cyst size, continued while the patient remains a surgical candidate; the remaining pancreas is followed after resection.40

Early / localised

SubgroupSettingApproachProducts and trialsEvidence
Risk groupHigh-risk stigmataResection (pancreatoduodenectomy or distal pancreatectomy) for obstructive jaundice, an enhancing mural nodule of 5 mm or more, a main duct of 10 mm or more, or positive cytology, in patients fit for surgery.40

Other settings

SubgroupSettingApproachProducts and trialsEvidence
All comersIncidental cystCharacterise with MRI and MRCP or pancreas-protocol CT; endoscopic ultrasound with fluid analysis when the cyst type is unclear or worrisome features are present.66
All comersWorrisome featuresEndoscopic ultrasound and fluid sampling; resection or short-interval surveillance depending on findings, age and fitness.40
All comersInvasive carcinoma in an IPMNStaged and treated as pancreatic ductal adenocarcinoma with resection and adjuvant chemotherapy.87

Lines and subgroups are parsed from the setting text of each standard-of-care row and can misclassify an unusual phrasing; the row’s own setting is always shown. Guideline chips reflect the NCCN category and ESMO-MCBS grade recorded on the cancer page, checked on its stated date. Not medical advice.